Replies to post #316541 on Option Millionaires

[jimmybob]

Biogen upgraded to Conviction Buy from Buy at Goldman Sachs
Goldman analyst Terence Flynn added Biogen to the Conviction Buy List and maintained a $338 price target saying he continues to see optionality Aducanumab, its lead pipeline Alzheimer's drug. He expects Phase 3 data in Q4 2019/Q1 2020 saying it could be the first disease modifying drugs on the market with a peak sales estimated at $12B. Further, the analyst views MS competition concerns as overdone and said the balance sheet is relatively under-levered